- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
IIb
Principal Investigator(s)
Salim S Abdool karim; Quarraisha Abdool Karim
Objective
This phase IIb, two-arm, double-blinded, randomised, placebo controlled trial comparing 1% Tenofovir gel with a placebo gel is an expanded safety and effectiveness trial involving 900 young women at risk of sexually transmitted HIV infection. Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study gel within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. All participants will receive HIV risk reduction counselling, condoms, and syndromic treatment of sexually transmitted infections, if required.
Prevention Option(s)
Microbicides
Arms and Assigned Interventions
Description
Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
Mode of Delivery
Gel
Products
1% tenofovir gel
ARMs
Experimental
Description
Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
Mode of Delivery
Gel
ARMs
Placebo Comparator
Official Code
Related Publications
Similar Trials
Trial Sponsors
Centre for the AIDS Programme of Research in South Africa; FHI 360; United States Agency for International Development (USAID); CONRAD
May 2007
March 2010
Enrollment
889
18
Years
40
Years
Population
Women
Sites
CAPRISA eThekwini Clinical Research Site
Durban, KwaZulu-Natal
South Africa
CAPRISA Vulindlela Clinical Research Site
Pietermaritzburg, KwaZulu-Natal
South Africa